Biogen: BeNeLuxA Spinraza Talks “Collaborative And Constructive" But Not Without Challenges
Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.
You may also be interested in...
Francis Arickx from the cross-country coalition BeNeLuxA spoke this month about how the initiative had delivered proof of concept and discussed why uniting across borders is important for delivering access to transformative but expensive medicines.
Norway and Denmark have signed an agreement for the joint procurement of medicines and have their eye on securing a lower price for Biogen’s orphan drug Spinraza.
In a BeNeLuxA first, Belgium and the Netherlands have reached an agreement with Biogen to reimburse rare disease treatment Spinraza after joint health technology assessment and pricing negotiations.